Proud To Be Part Of Arm: Advancing The Future Of Regenerative Medicine Together

Excellos is part of the Alliance for Regenerative Medicine (ARM), an international organization committed to promoting progress in cell and gene therapy. With hundreds of members spanning over 25 countries — including companies, research institutions, and advocacy groups — ARM serves as a hub for innovation, policy development, and cross-sector collaboration in regenerative medicine.

Being involved with ARM provides Excellos with valuable exposure to emerging trends, regulatory changes, and expert perspectives that inform our operations as a CDMO. This relationship helps us stay current with industry standards and participate in joint efforts to address challenges in production, scale-up, and regulatory navigation. It also strengthens our ability to assist clients in bringing advanced therapies to market efficiently and responsibly. In line with ARM’s goals, Excellos remains focused on supporting the development of new treatments that aim to improve patient outcomes and expand access to potentially life-changing therapies.